4474-91-3 (血管紧张素II,Angiotensin II human)

血管紧张素II;血管紧张素Ⅱ;[Ile5]-血管紧缩素 2;人血管紧张素II;人血管紧张素II相对分子质量标准物质;人血管紧张肽 II<电离质谱校准物>;血管紧张素II,人;血管紧张肽 II;血管紧张素2;血管紧张肽酰胺;增加压素;增血压素,HYPERTENSIN;人血管紧张肽II;醋酸血管紧张素II;

Angiotensin II,5-L-isoleucine-;Angiotensin Acetate II;Angiotensin II;Angiotensin II, Ang II;Angiotensin II, human;Human angiotension II Relative Molecular Weight;[ILE5]-ANGIOTENSIN 2;[Ile5]angiotensin II;Ang II;Angiotensin Ⅱ, huMan;ANGIOTENSIN-2;angiotensinii(mouse);ANTI-ANGIOTENSIN II;Asp1-Arg2-Val3-Tyr4-Ile5-His6-Pro7-Phe8;Asp-Arg-Val-Tyr-Ile-His-Pro-Phe;DRVYIHPF;H2N-DRVYIHPF-COOH;H-DRVYIHPF-OH;HUMAN;human angiotensin II;Hypertensin;Hypertensin II;ile(5)-angiotensini;TY-10721;Alanine,N-[1-[N-[N-[N-[N-(N2-L-a-aspartyl-L-arginyl)-L-valyl]-L-tyrosyl]-L-isoleucyl]-L-histidyl]-L-prolyl]-3-phenyl-,L- (6CI,7CI);10: PN: WO0212471 SEQID: 17 unclaimed sequence;12: PN: WO0239997 SEQID: 17unclaimed sequence;17: PN:US6610497 SEQID: 17 unclaimed sequence;17: PN: US6884771 SEQID: 17 unclaimedsequence;17: PN: US6989363 SEQID: 17 unclaimed sequence;1:PN: CN1706502 PAGE: 2 claimed sequence;1: PN: US6022696 SEQID: 2 unclaimedsequence;1: PN: WO0002905 SEQID: 1 claimed protein;Angiotensin II human;Angiotensin II (mouse);Angiotensin II (human);Giapreza;5-Isoleucine-angiotensin II;5-L-Isoleucineangiotensin II;Ile(5)-angiotensin II;1-8-Angiotensin I;isoleucine(5)-angiotensin II;CZGUSIXMZVURDU-JZXHSEFVSA-N;M089EFU921;Isoleucine5-angiotensin II;Angiotensin II, ile(5)-;Angiotensin ii [INN:JAN];Angiotensin II (USAN);Angiotensin Ⅱ,human;CHEBI:131170;C75211;DRVY-I*-HPF [I*= I(13C6,15N)];DTXSID4036778;Angiotensin II (human type);(3S)-3-amino-3-{[(1S)-1-{[(1S)-1-{[(1S)-1-{[(1S,2S)-1-{[(2S)-1-[(2S)-2-{[(1S)-1-carboxy-2-phenylethyl]carbamoyl}pyrrolidin-1-yl]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]carbamoyl}-2-methylbutyl]carbamoyl}-2-(4-hydroxyphenyl)ethyl]carbamoyl}-2-methylpropyl]carbamoyl}-4-[(diaminomethylidene)amino]butyl]carbamoyl}propanoic acid;32044-01-2, 4474-91-3 (salt);BDBM50236697;Angiotensin II (9CI);NS00074073;SCHEMBL9013957;1-L-Aspasaginyl-5-L-valyl angiotensin octapeptide;BDBM50228195;C01CX09;CHEBI:48432;Angiotensin II (human type) (JAN);Angiotensin II (acetate);Ang II (acetate);DRVYIHPF (acetate);D02014;HB3488;CHEBI:2719;DB11842;L-phenylalanine, L-alpha-aspartyl-L-arginyl-L-valyl-L-tyrosyl-L-isoleucyl-L-histidyl-L-prolyl-;Angiotensin-(1-8) Octapeptide;Angiotensin 2;ProteoMass(TM) Angiotensin II MALDI-MS Standard, vial of 10 nmol;UNII-M089EFU921;C50H71N13O12;AKOS016010178;Angiotensina II (INN-Spanish);DTXSID30196288;C02135;Angiotensin II heavy;HY-13948;Delivert;Angiotensinum II;(3S)-3-AMINO-3-{[(1S)-4-CARBAMIMIDAMIDO-1-{[(1S)-1-{[(1S)-1-{[(1S,2S)-1-{[(2S)-1-[(2S)-2-{[(1S)-1-CARBOXY-2-PHENYLETHYL]CARBAMOYL}PYRROLIDIN-1-YL]-3-(1H-IMIDAZOL-4-YL)-1-OXOPROPAN-2-YL]CARBAMOYL}-2-METHYLBUTYL]CARBAMOYL}-2-(4-HYDROXYPHENYL)ETHYL]CARBAMOYL}-2-METHYLPROPYL]CARBAMOYL}BUTYL]CARBAMOYL}PROPANOIC ACID;SCHEMBL1189;ANG-(1-8)Octapeptide, Hypertensin, 4474-91-3, Giapreza;Alanine, N-(1-(N-(N-(N-(N-(N2-L-alpha-aspartyl-L-arginyl)-L-valyl)-L-tyrosyl)-L-isoleucyl)-L-histidyl)-L-prolyl)-3-phenyl-, L-;4474-91-3;(2S,5S,8S,11S,14S,17S)-2-((1H-imidazol-4-yl)methyl)-17-amino-5-((S)-sec-butyl)-1-((S)-2-(((S)-1-carboxy-2-phenylethyl)carbamoyl)pyrrolidin-1-yl)-14-(3-guanidinopropyl)-8-(4-hydroxybenzyl)-11-isopropyl-1,4,7,10,13,16-hexaoxo-3,6,9,12,15-pentaazanonadecan-19-oic acid;CHEMBL408403;A872469;L-alpha-aspartyl-L-arginyl-L-valyl-L-tyrosyl-L-isoleucyl-L-histidyl-L-prolyl-L-phenylalanine;Delivert (TN);NCGC00167130-01;(2S,5S,8S,11S,14S,17S)-2-((1H-imidazol-5-yl)methyl)-17-amino-5-((S)-sec-butyl)-1-((S)-2-(((S)-1-carboxy-2-phenylethyl)carbamoyl)pyrrolidin-1-yl)-14-(3-((diaminomethylene)amino)propyl)-8-(4-hydroxybenzyl)-11-isopropyl-1,4,7,10,13,16-hexaoxo-3,6,9,12,15-pentaazanonadecan-19-oic acid;Q412999;Conalbumin (328-332), 1226776-54-0, RVPSL peptide;LJPC-501;ANG-(1-8)Octapeptide;Ile5-angiotensin II;Angiotensin II, 5-L-isoleucine-;angiotensine II;EN300-19742056;N-(1-(N-(N-(N-(N-(N(2)-L-alpha-aspartyl-L-arginyl)-L-valyl)-L-tyrosyl)-L-isoleucyl)-L-histidyl)-L-prolyl)-L-phenylalanine;L-Phenylalanine, N-(1-(N-(N-(N-(N-(N2-L-alpha-aspartyl-L-arginyl)-L-valyl)-L-tyrosyl)-L-isoleucyl)-L-histidyl)-L-prolyl)-;SCHEMBL20502357;GTPL2504;Angiotensinum II (INN-Latin);ANGIOTENSINII,HUMAN;DA-70862;Angiotensin II acetate salt;

MFCD00161484

CZGUSIXMZVURDU-JZXHSEFVSA-N

1S/C50H71N13O12/c1-5-28(4)41(47(72)59-36(23-31-25-54-26-56-31)48(73)63-20-10-14-38(63)45(70)60-37(49(74)75)22-29-11-7-6-8-12-29)62-44(69)35(21-30-15-17-32(64)18-16-30)58-46(71)40(27(2)3)61-43(68)34(13-9-19-55-50(52)53)57-42(67)33(51)24-39(65)66/h6-8,11-12,15-18,25-28,33-38,40-41,64H,5,9-10,13-14,19-24,51H2,1-4H3,(H,54,56)(H,57,67)(H,58,71)(H,59,72)(H,60,70)(H,61,68)(H,62,69)(H,65,66)(H,74,75)(H4,52,53,55)/t28-,33-,34-,35-,36-,37-,38-,40-,41-/m0/s1

O=C([C@H](CC1=CN=CN1)NC([C@H]([C@@H](C)CC)NC([C@H](CC1C=CC(=CC=1)O)NC([C@H](C(C)C)NC([C@H](CCC/N=C(\N)/N)NC([C@H](CC(=O)O)N)=O)=O)=O)=O)=O)N1CCC[C@H]1C(N[C@H](C(=O)O)CC1C=CC=CC=1)=O

用于生化和医学研究，直接作用于肾上腺刺激醛固酮的释放，医药上用于外伤性和手术后休克和全身或腰椎麻醉所至的低血压。;升血压药。用于外伤性或手术后休克和全身或腰椎麻醉所致的低血压。不良反应和禁忌：有时可引起眩晕、头痛，偶致心绞痛。过量可致心动过缓。失血过多引起的低血压应补充血容量。心功能不全者慎用。;

增血压素的化学合成工艺取苄氧羰酰苯丙氨酸叔丁酯溶于甲醇，加入5%钯炭，不断振摇下通入氢气6h，然后过滤，滤液浓缩至干，得苯丙氨酸叔丁酯。另取等摩尔苄氧羰酰脯氨酸和苯丙氨酸叔丁酯溶于乙酸乙酯中，冰浴冷却，加入适量二环己基碳二亚胺，冷藏2天，取出过滤去杂质，滤液以枸橼酸、氯化钠、碳酸氢钠、氯化钠溶液分别依次洗涤3次，用无水硫酸钠干燥，浓缩，得苄氧羰酰脯·苯丙叔丁酯。将苄氧羰酰脯·苯丙叔丁酯溶于甲醇，加入钯炭(5%)，通人氢气振摇6h，然后过滤，滤液浓缩至干，得脯·苯丙叔丁酯。取苄氧羰酰缬氨酰组氨酸酰肼溶于2mol/L盐酸中，加入乙酸乙酯，在0℃下加入过量的亚硝酸钠溶液(10%)反应10min，用碳酸钾调节pH 9以上，加入乙酸乙酯提取3次，合并提取液，用氯化钠溶液洗涤提取液，无水硫酸钠干燥，得苄氧羰酰缬·组叠氮。把苄氧羰酰缬·组叠氮液体倒人脯·苯丙叔丁酯中，置冰箱2天，然后用枸橼酸、氯化钠、碳酸氢钠、氯化钠液依次分别洗涤，用无水硫酸钠干燥，得苄氧羰酰缬·组·脯·苯丙叔丁酯，然后将其溶于甲醇中，加入5%钯炭，通人氢气，并不断振摇6h，反应完毕后，过滤，滤液浓缩，得缬·组·脯·苯丙叔丁酯。取苄氧羰酰缬氨酰酪氨酸酰肼溶于二甲基甲酰胺-乙酸乙酯—盐酸混合液中，于-20℃下慢慢加入亚硝酸叔丁醇，搅拌10min后用三乙胺调节至中性，过滤，得苄氧羰酰缬·酪叠氮滤液。滤液加入缬·组·脯·苯丙叔丁酯中，冷藏2天，加人大量乙醚。过滤沉淀，干燥即得苄氧羰酰缬·酪·缬·组·脯·苯丙叔丁酯。将苄氧羰酰缬·酪·缬·组·脯·苯丙叔丁酯溶于甲醇中，加入10％钯炭，通入氢气，并不断振摇6h后，过滤，滤液浓缩，得苄氧羰酰缬·酪·缬·组·脯·苯丙叔丁酯。取苄氧羰酰天冬酰胺酰硝基精氨酸和苄氧羰酰缬·酪·缬·组·脯·苯丙叔丁酯溶于二甲基甲酰胺中，加入二环己基碳二亚胺溶液，于35℃保温3天。过滤，滤液加入碳酸氢钠溶液，得白色沉淀，过滤，沉淀物用乙醇-乙醚混合液洗涤，得酪·缬·组·脯·苯丙叔丁酯。将酪·缬·组·脯·苯丙叔丁酯加入三氟乙酸中，于30℃振摇4h，然后加入无水乙醚，收集沉淀干燥，得苄氧羰酰天胺·硝基精·缬·酪·缬·组·脯·苯丙。将苄氧羰酰天胺·硝基精·缬·酪·缬·组·脯·苯丙溶于甲醇-盐酸中，加入钯炭，通人氢气振摇8h，反应完毕，过滤，滤液用弱碱性苯乙烯系阴离子交换树脂303×2(704)调节pH至中性，过滤，滤液浓缩至干，乙醚洗涤，过滤，干燥，即得增血压素，生物活力达60%以上。从苄氧羰酰苯丙氨酸叔丁酯出发，以相应的保护氨基酸单体为原料，用固相法合成，再精制而得。